louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00639977: Effect of Acupuncture on Intraocular Pressure
Official title: Effect of Acupuncture on Intraocular Pressure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Healthy
Keywords: Intraocular Pressure
Acupuncture
Healthy Volunteers
Lead sponsor: Federal University of São Paulo
Sponsor class: OTHER
First posted: 2008-03-20
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the short-term effect of acupuncture on the intraocular pressure (IOP).

Methods: A randomized controlled trial. Healthy volunteers will be randomly allocated to three groups: Acupuncture group - will be submitted to a 20-minute session of acupuncture with needles inserted in specific points (Tong Zi Liao, Yang Bai and Jing Ming); Sham group - will be submitted to a 20- minute session of acupuncture with needles inserted in false points located 1 cm from true points in areas without acupuncture's meridians; and Control group - no intervention. IOP measurement by a masked investigator using Goldmann applanation tonometry immediately before the intervention, as well as 30 minutes and 24 hours after the acupuncture.


Eligibility criteria: Inclusion Criteria:

* healthy volunteers

Exclusion Criteria:

* glaucoma
* past intraocular surgery
* corneal alterations
* medications that interferes with the intraocular pressure

Primary outcomes:
measure: variation of the intraocular pressure
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Departamento de Oftalmologia - UNIFESP
state: SP
Study officials:
affiliation: Universidade Federal de São Paulo
name: Daniel Meira-Freitas, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Universidade Federal de São Paulo
name: Angelino J Cariello, MD
role: STUDY_CHAIR
affiliation: Universidade Federal de São Paulo
name: Luiz Alberto S Melo Jr., MD
role: STUDY_DIRECTOR
References:
citation: Meira-Freitas D, Cariello AJ, Vita RC, Tabosa A, Melo LA Jr. Short-term effect of acupuncture on intraocular pressure in healthy subjects. Acupunct Med. 2010 Mar;28(1):25-7. doi: 10.1136/aim.2009.001081.
Clinical trial NCT03225677: Novel Tracer Methods to Evaluate Muscle Protein Metabolism in Cirrhosis
Official title: Multiple Tracer Using Single Muscle Biopsy Technique in Evaluating Protein Synthesis and Break Down in Muscles of Cirrhotic Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cirrhosis
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
First posted: 2017-07-21
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study population: Adults with the diagnosis of cirrhosis will be recruited from the hepatology inpatient service, outpatient clinics and liver transplant clinics at the Cleveland Clinic Foundation. The diagnosis of cirrhosis will be based on liver biopsy and/or clinical, biochemical, and imaging criteria. Will include patient with Child Pugh score from A5- to B7

Brief summary: To determine the rate and mechanisms of skeletal muscle protein synthesis and breakdown in cirrhotic patients by using multiple tracers and single muscle biopsies.

Detailed description: The goal of this study is to identify the molecular regulatory mechanisms that result in loss of skeletal muscle in cirrhotic patients. Current strategies involve prolonged tracer infusion and multiple muscle biopsies. We will use an innovative approach to determine the rates of skeletal muscle protein synthesis and breakdown using multiple tracers administered at short intervals followed by a single muscle biopsy. These studies are likely to provide a conceptual advance in determining the cellular and molecular responses of the skeletal muscle in cirrhosis.

Eligibility criteria: Inclusion Criteria:

* The diagnosis of cirrhosis based on liver biopsy and/or clinical, biochemical, and imaging criteria.
* Patients with Child Pugh score from A5- to B7
* Control group: Subject in control group should have serum ALT and AST within normal range.

Exclusion Criteria for both groups (cirrhotic and control) are:

* diabetes
* cancer
* kidney failure
* pregnancy
* recent surgery (bowel resection or Gastric bypass operation)
* Advanced cardiac or pulmonary disease
* patient with thyroid disease \& Coagulopathy ( INR \>1.4 and platelet count \<80,000/ml)

Primary outcomes:
measure: Fractional Synthesis Rate
timeFrame: 4 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic Foundation
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Srinivasan Dasarathy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03826277: Efficacy of Melanostop Peeling for Improvement of Melasma
Official title: The Efficacy of Melanostop Peel in Combination With Specifically Selected Home Care Regimen for Improvement of Melasma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Melasma
Lead sponsor: VIST - Faculty of Applied Sciences
Sponsor class: OTHER
First posted: 2019-02-01
Enrollment: 10
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Participants with face melasma will receive 4 Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol and 6% phytic acid. Peels will be performed at 2-week interval. They will also receive a facial tonic and cream for at home use, containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid. They will also receive sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR. Products for at home use will be used twice a day, every day. Measurements will be made at baseline, on the day of the forth peel treatment and 4 weeks after the last peel. Measured parameters will be: mMASI score, VisioFace photography analysis, melasma area measurements, and melanin index, ΔE, CIELab colour measurements with Cortex SkinLab Combo (Cortex Technology Asp, Denmark).


Eligibility criteria: Inclusion Criteria:

* Adult women aged between 20-50 years old.
* Melasma on the face
* Fitzpatrick phototypes I-IV
* Presenting facial melasma
* In good health condition

Exclusion Criteria:

* Breastfeeding and pregnancy
* Women presenting oral herpes
* Other skin diseases, arthritis, diabetes, diseases of thyroid gland
* Any known allergies to ingredients of the products used in the study
* Systemic or topical use of corticosteroids in the previous 6 months
* Antiaging or lightening cosmetic/estetic procedures in the last 2 months (for example: laser or IPL treatments, chemical peels,..)
* Taking drugs for skin lightening in the previous 2 months
* Smoking
* Lesions of unknown origin
* Oral or topical use of isotretinoin in the previous 6 months
* Active bacterial, viral or fungal infections of the skin
* Presence of keloid scars
* Immunodeficiency
* Moderate to severe acne
* Planned change in hormonal contraception or taking drugs that have an affect on hormonal balance during the course of the study
* Unrealistic expectations
* Refusal to use sunscreen protection and complying with instructions

Primary outcomes:
measure: Modified Melasma Area and Severity Index (mMASI)
timeFrame: week 1, week 7, week 11
measure: Colour difference
timeFrame: week 1, week 7, week 11
measure: Melanin index change
timeFrame: week 1, week 7, week 11
measure: Area of the melasma
timeFrame: week 1, week 7, week 11
Secondary outcomes:
Other outcomes:
Locations:
city: Ljubljana
country: Slovenia
facility: Higher School of Applied Sciences, Institute of Cosmetics
Study officials:
affiliation: Head of Reasearch Group
name: Katja Žmitek, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01639677: Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity
Official title: Randomized Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Morbid Obesity
Keywords: Obesity
weight loss
surgery
gastric bypass
VBG
Lead sponsor: Göteborg University
Sponsor class: OTHER
Collaborators: name: Imperial College London
First posted: 2012-07-13
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized clinical trial assessing the outcome of two surgical strategies to treat severe obesity; laparoscopic gastric bypass and laparoscopic VBG. Main outcome is weight loss and weight loss maintenance but other factors as body composition, eating pattern, metabolic normalisation, energy expenditure will also be assessed.


Eligibility criteria: Inclusion Criteria:

* BMI 35-50 kg/m2
* 20-60 y

Exclusion Criteria:

* Severe co-morbidity
* Unmotivated to long term follow up

Primary outcomes:
measure: Weight loss
timeFrame: 1, 2, 5 and 10 years after surgery
Secondary outcomes:
measure: Body composition
timeFrame: 1, 2, 5 and 10 years after surgery
measure: Eating pattern
timeFrame: 1, 2, 5 and 10 years after surgery
measure: Energy expenditure
timeFrame: 1, 2, 5 and 10 years after surgery
measure: Gut hormonal response
timeFrame: 4 and 10 years after surgery
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Department of Surgery
Study officials:
affiliation: GöteborgU
name: Torsten Olbers, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01149577: Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Schizophrenia
Sleep
Keywords: Olanzapine
Schizophrenia
Polysomnography
Slow wave sleep
Lead sponsor: Central Institute of Psychiatry, Ranchi, India
Sponsor class: OTHER
First posted: 2010-06-23
Enrollment: 25
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Acute and sub-chronic administration of olanzapine has shown a favourable effect on the sleep disturbances in previously medicated schizophrenia patients with predominantly negative symptoms. The present study will be carried out to clarify the effect of olanzapine on polysomnographic profiles of schizophrenia patients in an acute phase of illness after controlling for the drug effects.

Detailed description: Twenty schizophrenia patients (11 drug naïve and 9 drug free) will be studied over a period of six weeks of olanzapine treatment. Patients will be assessed at the baseline on BPRS, PANSS, CDSS and UKU side effect rating scales and a baseline 40 channels polysomnography will be done. After the initial assessment, patients will put on olanzapine treatment, in flexible dosages based on clinical response, for a period of six weeks when a final assessment on clinical rating scales and polysomnography will be done. The sleep data will be scored manually for staging based on Rechtschaffen and Kales criteria.

Eligibility criteria: Inclusion Criteria:

1. Male patients fulfilling International Classification of Diseases-10 Diagnostic Criteria for Research for schizophrenia
2. Aged 18-50 Yrs
3. Drug naïve or drug free (not receiving any psychotropic medication for the past 4 months)
4. Consenting

Exclusion Criteria:

1. Any comorbid psychiatric illness
2. Significant medical or neurological illness
3. History of significant head injury, epilepsy
4. Substance use in the past 4 months excluding nicotine and caffeine
5. Presence of a primary sleep disorder

Primary outcomes:
measure: Sleep EEG
timeFrame: 06 weeks
Secondary outcomes:
measure: Psychopathology
timeFrame: 06 weeks
Other outcomes:
Locations:
city: Ranchi
country: India
facility: Central Institute of Psychiatry
state: Jharkhand
Study officials:
affiliation: Central Institute of Psychiatry
name: Mohammad Zia Ul Haq Katshu, DPM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05037877: An Exploratory Investigation of Dietary Supplementation and Its Effect
Official title: An Exploratory Investigation of Dietary Supplementation and Its Effect
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Quality of Life
Lead sponsor: HUM Nutrition, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Citruslabs
First posted: 2021-09-08
Enrollment: 110
Sex: FEMALE
Minimum age (years): 38
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This will be a 2-arm randomized, double-blinded, placebo-controlled study
Primary purpose: OTHER

Brief summary: The primary objective of this study is to understand if the test product (HUM supplement) improve symptoms experienced.

Detailed description: This will be a 2-arm randomized, double-blinded, placebo-controlled study.

Eligibility criteria: Inclusion Criteria:

* Female
* Willing to maintain the current dietary pattern, activity level, and stable body weight for the duration of the study
* Must be in good health (don't report any medical conditions asked in the screening questionnaire)
* Willing and able to provide written informed consent

Exclusion Criteria:

* Allergies to any test product ingredients
* Any other severe chronic disease
* Pregnant, want to become pregnant for the duration of the study, or who are breastfeeding
* Participating in an investigational health product research study

Primary outcomes:
measure: Quality of life improvements [Time Frame: Baseline to 8 weeks)
timeFrame: 8 week
Secondary outcomes:
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: Citruslabs
state: California
Study officials:
affiliation: Citruslabs
name: Susanne Mitschke
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06470477: Molecular Characteristics of Phlegm-heat Syndrome in Ischemic Stroke
Official title: Molecular Characteristics of Phlegm-heat Syndrome in Ischemic Stroke: A Cohort Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Ischemic Stroke, Acute
Lead sponsor: Dongzhimen Hospital, Beijing
Sponsor class: OTHER
First posted: 2024-06-24
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients aged 18 to 80 years with acute ischemic stroke within 72 hours of onset.

Brief summary: The molecular characteristics of ischemic stroke with phlegm-heat syndrome and candidate biomarkers were identified based on multi-omics data. The main purpose of this study is to validate the molecular characteristics and biomarkers of phlegm-heat syndrome in ischemic stroke, and to demonstrate the association of biomarkers with clinical outcomes.

Detailed description: This is a cohort study in patients with acute ischemic stroke. The demographic characteristics, Traditional Chinese Medicine (TCM) syndromes, and other baseline information will be recorded. At the same time, baseline peripheral blood will be collected. These participants will be followed up to 90 days of onset, and 90-day modified Rankin scale (mRS) scores will be assessed. The collected blood samples will be tested by multi-factor detection technology for candidate biomarkers.

Eligibility criteria: Inclusion Criteria:

* Acute ischemic stroke.
* Symptom onset within 72 hours.
* Diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome.
* Male or female ≥18 years and ≤ 80 years.
* With written informed consent.

Exclusion Criteria:

* Acute infectious diseases or acute exacerbations of chronic diseases within one month before enrollment.
* Patients has previous stroke.
* Other conditions that lead to motor dysfunction (e.g., severe osteoarthritis, rheumatoid arthritis).
* Renal or hepatic insufficiency, tumors, immune diseases, severe underlying diseases.
* Other conditions that affect the collection and evaluation of clinical information (e.g., severe aphasia, mental illness).

Primary outcomes:
measure: Sensitivity, specificity, and area under the ROC curve of molecular features of Phlegm-heat syndrome in ischemic stroke
timeFrame: Baseline
Secondary outcomes:
measure: Proportion of patients independent
timeFrame: 90 days
measure: National Institute of Health Stroke Scale
timeFrame: Baseline, 7 days and 10 days after stroke onset.
Other outcomes:
Locations:
city: Beijing
country: China
facility: Dongzhimen Hospital
state: Beijing
Study officials:
affiliation: Dongzhimen Hospital, Beijing
name: Ying Gao, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03711877: Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)
Official title: Comparative Study of Scalp Cooling System and Chemical Cold Cap on Prevention of Chemotherapy-induced Alopecia in Women With Breast Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Primary Breast Cancer
Keywords: alopecia
scalp cooling system
cold cap
Lead sponsor: Peking University
Sponsor class: OTHER
First posted: 2018-10-19
Enrollment: 256
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a phase III, single-center, prospective, open-label, randomized,controlled study

Detailed description: To conduct a prospective randomized controlled study comparing the effect of scalp cooling system (DigniCap) and chemical cold cap on preventing chemotherapy-induced alopecia in a group of breast cancer patients receiving standard anthracycline followed paclitaxel regimens. To obtain the exact data on the role of different methods of preventing alopecia in Chinese women with breast cancer.

PASS 11 software was used to calculate the sample size. According to the results of previous studies, the hair retention rate of the cold cap group was 67.7%, the hair retention rate of the scalp cooling system group was 50.5%, α=0.05，Power=0.8. The sample size was calculated to be at least 128 cases in each group, 256 cases in total.

Eligibility criteria: Inclusion Criteria:

* Female patients, 18≦age ≦66 years
* Invasive breast cancer diagnosed with core needle needle biopsy
* Staging I-II
* Without chemotherapy contraindications, and planned to receive neoadjuvant chemotherapy with a standard regimen (containing 4-cycle dose-dense anthracycline followed 4-cycle paclitaxel)
* Attend the study voluntarily, sign the informed consent

Exclusion Criteria:

* History of malignant tumors
* With chemotherapy contraindications
* With severe dermatosis and severe sparsity
* History of chronic diseases such as cerebrovascular disease, migraine and hyperthyroidism
* Uncontrolled diseases(e.g., heart failure, myocardial infarction within 6 months, arrhythmia, unstable diabetes, hypercalcemia) or active infection
* Refuse to join the study

Primary outcomes:
measure: The effects on the prevention of alopecia of two methods
timeFrame: One year after neoadjuvant chemotherapy
Secondary outcomes:
measure: Qualify of life
timeFrame: One year after neoadjuvant chemotherapy
measure: Psychological stress
timeFrame: One year after neoadjuvant chemotherapy
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Cancer Hospital
state: Beijing
Study officials:
affiliation: Peking University Cancer Hospital & Institute
name: Xinying Yu, Master
role: STUDY_DIRECTOR
References:
Clinical trial NCT02138877: Dismembered Pyeloplasty With and Without After Coming Stent
Official title: Dismembered Pyeloplasty With and Without After Coming Stent in Neonatal Ureteropelvic Junction Obstruction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pelviureteric Junction Obstruction
Pyeloplasty
Neonatal Hydronephrosis
Obstructive Uropathy
Urinary Stent
Keywords: Pelviureteric junction obstruction
pyeloplasty
Neonate affected by hydronephrosis
obstructive uropathy
urinary stent
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2014-05-15
Enrollment: 30
Sex: ALL
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: to compare outcome of pyeloplasty in pediatric population less than 6 months in age using an after coming stent versus stentless pyeloplasty.

Detailed description: A prospective randomized control study including patients divided into two groups,all patient undergoes dismembered pyeloplasty First group will be with an after coming stent ,Second group will be stentless to compare outcome of pyeloplasty in pediatric population less than 6 months in age

Eligibility criteria: Inclusion Criteria:

* Pelvi-ureteric junction obstruction (PUJO)
* Asymptomatic obstruction with reduced function (less than 35-40%)
* Asymptomatic obstruction with antero-posterior diameter exceed 40 mm
* Asymptomatic obstruction with deterioration on conservative follow up.
* Symptomatic PUJ obstruction, e.g. pain, renal mass, fever and stones.

Exclusion Criteria:

* Secondary Pelvi-ureteric junction obstruction
* Solitary kidney
* Gross pyuria
* Ectopic kidney
* Dilated ureter

Primary outcomes:
measure: Postoperative Hospital stay
timeFrame: 1 week
measure: Leakage
timeFrame: 1 week
measure: 2ry intervention
timeFrame: 1 month
measure: Fever
timeFrame: 1 month
Secondary outcomes:
measure: Assessment of kidney function after repair
timeFrame: 6 months
measure: success
timeFrame: 6 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University Hospitals
Study officials:
affiliation: Cairo University
name: Mohammed S ElSheemy, A professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05225077: Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
Official title: Effect of Short-term Dapagliflozin on Renal Function After Heart Catheterization or Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Renal Insufficiency, Chronic
Cardiac Catheterization
Percutaneous Coronary Intervention
Keywords: Sodium-Glucose Transporter 2 Inhibitors
Dapaglifozin
Chronic kidney disease
Lead sponsor: Dong-A University
Sponsor class: OTHER
First posted: 2022-02-04
Enrollment: 600
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as observed the incidence of CIN.


Eligibility criteria: Inclusion Criteria:

* Age\>18 years
* Written informed consent
* Glomerular Filtration Rate (GFR)≥ 30 ml/min/1.73m2 \[CKD stage G1-G3\]
* Percutaneous coronary intervention in patients with NSTEMI, UA, STCD and asymptomatic patients

Exclusion Criteria:

* Active malignancy
* Class I or equivalent indication for treatment with a SGLT2 inhibitor
* Pregnancy or willing of pregnancy during the follow up period
* Active urogenital infection
* Diabetes mellitus type 1
* History of diabetic ketoacidosis
* Cardiogenic shock
* eGFR \< 29 ml/min/1.73m2

Primary outcomes:
measure: Incidence of contrast induced nephropathy
timeFrame: 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: Dong A University Hospital
Study officials:
References: